Corline Biomedical (CLBIO) Q2 2025 earnings summary

Executive summary

• Positioned for a breakthrough as a CHSTM supplier to the US market, leveraging a professional team and focus on quality to build long-term market relevance.

• Strategic focus on supporting Kardium's US launch and expanding the customer base through the Growth Initiative targeting new medtech clients.

Financial highlights

• Net sales for Q2 2025 were 2,187 KSEK, nearly flat compared to Q2 2024 (2,255 KSEK).

• Net sales for H1 2025 totaled 4,242 KSEK, down from 5,993 KSEK year-over-year.

• Result after financial items for Q2 2025 was -3,257 KSEK, an improvement from -4,369 KSEK in Q2 2024.

• H1 2025 result after financial items was -6,328 KSEK, slightly worse than -6,038 KSEK in H1 2024.

• Cash and cash equivalents at June 30, 2025, were 8.3 MSEK, down from 12.7 MSEK a year earlier.

Outlook and guidance

• Future growth depends on Kardium's upcoming US product launch and FDA approval, with no major production investments planned for the next three years.

• The Growth Initiative aims to diversify the customer base and increase revenue by targeting both large and small medtech clients.

• Financial stability in the near term relies on increased sales, particularly from the Kardium contract.